[Effect of peroxisome proliferator-activated receptors activators on plasminogen activator inhibitor-1 expression in HepG-2 cells]. 2003

Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
Center of Gene Diagnosis, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.

OBJECTIVE To investigate the effect of different peroxisome proliferator-activated receptors (PPARs) activators on plasminogen activator inhibitor-1 in HepG-2 cell line and explore the effect of PPARs on PAL-1 gene expression. METHODS Stearic acid, oleic acid, linoleic acid, fenofibrate, pioglitazone were used in the treatment of HepG-2 cell culture. The level of PAI-1 and PPARs mRNA was measured by reverse transcription-polymerase chain reaction (RT-PCR) and the level of PAI-1 activity and PPARs protein was determined by colorimetric assay and western blotting respectively. RESULTS The mRNA and activity of PAI-1 significantly increased in the groups of oleic acid and linoleic acid compared with the control, but decreased in the group of fenofibrate. There were no significant changes in both groups of stearic acid and pioglitazone. The alterations in the level of PPARs mRNA and protein were not detected in all the treated groups compared with the control. CONCLUSIONS Peroxisome proliferator-activated receptors activators play important roles in the PAI-1 gene expression and regulation. It is likely mediated by the activation of PPARalpha, but there might be other mechanisms.

UI MeSH Term Description Entries
D011345 Fenofibrate An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. Procetofen,Antara Micronized Procetofen,Apo-Feno-Micro,Apo-Fenofibrate,CiL,Controlip,Fenobeta,Fenofanton,Fenofibrat AL,Fenofibrat AZU,Fenofibrat AbZ,Fenofibrat FPh,Fenofibrat Heumann,Fenofibrat Hexal,Fenofibrat Stada,Fenofibrat-ratiopharm,Fénofibrate Debat,Fénofibrate MSD,Gen-Fenofibrate,LF-178,Lipanthyl,Lipantil,Liparison,Lipidil,Lipidil-Ter,Livesan,Lofibra,MTW-Fenofibrat,Normalip,Novo-Fenofibrate,Nu-Fenofibrate,PMS-Fenofibrate Micro,Phenofibrate,Procetofene,Secalip,Supralip,Tricor,durafenat,fenofibrat von ct,AZU, Fenofibrat,Apo Feno Micro,Apo Fenofibrate,Debat, Fénofibrate,Fenofibrat ratiopharm,Gen Fenofibrate,Heumann, Fenofibrat,Hexal, Fenofibrat,LF 178,LF178,Lipidil Ter,MTW Fenofibrat,Micronized Procetofen, Antara,Novo Fenofibrate,Nu Fenofibrate,PMS Fenofibrate Micro,Procetofen, Antara Micronized,Stada, Fenofibrat
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D017395 Plasminogen Activator Inhibitor 1 A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators. PAI-1,SERPINE1 Protein,Serpin E1,Type 1 Plasminogen Activator Inhibitor,E1, Serpin,Protein, SERPINE1
D047492 Peroxisome Proliferator-Activated Receptors TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes. Peroxisome Proliferator-Activated Receptor,NUC1 PPAR,PPAR,PPAR, NUC1,Peroxisome Proliferator Activated Receptor,Peroxisome Proliferator Activated Receptors,Proliferator-Activated Receptor, Peroxisome,Proliferator-Activated Receptors, Peroxisome,Receptor, Peroxisome Proliferator-Activated,Receptors, Peroxisome Proliferator-Activated
D056945 Hep G2 Cells A human liver tumor cell line used to study a variety of liver-specific metabolic functions. Cell Line, Hep G2,Cell Line, Hepatoblastoma G2,Hep G2 Cell Line,HepG2 Cells,Hepatoblastoma G2 Cell Line,Cell, Hep G2,Cell, HepG2,Cells, Hep G2,Cells, HepG2,Hep G2 Cell,HepG2 Cell
D019301 Oleic Acid An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed) 9-Octadecenoic Acid,Oleate,cis-9-Octadecenoic Acid,9 Octadecenoic Acid,cis 9 Octadecenoic Acid
D019787 Linoleic Acid A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed) 9,12-Octadecadienoic Acid,Linoleate,9-trans,12-trans-Octadecadienoic Acid,Linoelaidic Acid,Linoelaidic Acid, (E,Z)-Isomer,Linoleic Acid, (E,E)-Isomer,Linoleic Acid, (Z,E)-Isomer,Linoleic Acid, (Z,Z)-Isomer,Linoleic Acid, (Z,Z)-Isomer, 14C-Labeled,Linoleic Acid, Ammonium Salt, (Z,Z)-Isomer,Linoleic Acid, Calcium Salt, (Z,Z)-Isomer,Linoleic Acid, Potassium Salt, (Z,Z)-Isomer,Linoleic Acid, Sodium Salt, (E,E)-Isomer,Linoleic Acid, Sodium Salt, (Z,Z)-Isomer,Linolelaidic Acid,cis,cis-9,12-Octadecadienoic Acid,trans,trans-9,12-Octadecadienoic Acid,9 trans,12 trans Octadecadienoic Acid,9,12 Octadecadienoic Acid,Acid, 9,12-Octadecadienoic

Related Publications

Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
June 2002, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
October 2004, Zhonghua nei ke za zhi,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
January 2003, Chinese medical journal,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
December 1996, Annals of the New York Academy of Sciences,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
January 1997, Cancer,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
January 2009, PPAR research,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
June 2013, Cancer science,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
January 1993, Experimental nephrology,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
October 2003, Diabetes research and clinical practice,
Yan-Li He, and Xin Zhou, and Ping Ye, and Hong Fang, and Yong-Xue Liu, and Cheng-Hua Luo, and Qiong Wang
February 2005, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!